Compare CAC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | REPL |
|---|---|---|
| Founded | 1875 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.2M | 692.8M |
| IPO Year | 1996 | 2018 |
| Metric | CAC | REPL |
|---|---|---|
| Price | $46.42 | $7.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $45.50 | $11.13 |
| AVG Volume (30 Days) | 72.2K | ★ 1.4M |
| Earning Date | 05-05-2026 | 02-03-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 6.08 | 5.25 |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $41,739,000.00 | N/A |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $34.53 | $2.68 |
| 52 Week High | $51.57 | $13.24 |
| Indicator | CAC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 45.35 |
| Support Level | $42.36 | $6.71 |
| Resistance Level | $46.86 | $8.82 |
| Average True Range (ATR) | 1.07 | 0.46 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 78.13 | 40.51 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.